-
JBCRG-15
Clinical pharmacology study of anti-estrogen based on pharmacogenomics and pharmacokinetics for hormone-sensitive breast cancer patients
- Status
-
Study Closed
- Objectives
-
Investigate the difference in toremifen metabolite concentration between 40mg and 120mg in patients who are poor metaboliser for tamoxifen
- Subjects
-
- Endpoints
-
Change in toremifen metabolite concentration between 40mg and 120mg
- Trial Period
-
2 years entry
- Lead Principal Investigator
-
Hiroshi Ishiguro (Outpatient Oncology Unit, Kyoto University Hospital)
- Target Sample Size
-
30
- Regimen
-
Toremifen 40mg PO, Dose escaration to 120mg
- Source of Funding
-
JBCRG(Japan Breast Cancer Research Group)
- Conference Presentation
-
Pharmacogenomics-pharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients (JBCRG-12,15)
- Articles and Publications
-
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer (JBCRG-12/15)
- UMIN-ID
-
UMIN000002632
- jRCT
-
- Memo
-
- COI Disclosure
-
